PATHOGENESIS AND TACTICS OF TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS: THE ROLE OF ALFACALCIDOL


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The glucocorticoids (GC) are widely used in modern clinical practice. However, side effects developing on the background of long-term use of drugs of this group are often equal to the severity and health-social value of the underlying disease. One of these complications is a glucocorticoid-induced osteoporosis (GIO) and associated bone fractures. In current clinical guidelines, vitamin D active metabolites occupy separate place in the treatment of GIO, because they are able to neutralize many of the negative effects of GC on bone, muscle tissue and calcium-phosphorus metabolism in general. In particular, alfacalcidol can be successfully used for the treatment of GIO both as monotherapy and in combination with bisphosphonates.

Full Text

Restricted Access

About the authors

L. A Marchenkova

FSBI «Russian Research Center of Medical Rehabilitation and Balneology» of RMH

MD, Head of Department of Endocrinology Moscow

References

  1. Diez-Perez A., Hooven F.H., Adachi J.D., Adami S., Anderson F.A., Boonen S., Chapurlat R., Compston J.E., Cooper C., Delmas P., Greenspan S.L., Lacroix A.Z., Lindsay R., Netelenbos J.C., Pfeilschifter J., Roux C., Saag K.G., Sambrook P., Silverman S., Siris E.S., Watts N.B., Nika G., Gehlbach S.H. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011;49:493-98.
  2. Болезнь Иценко-Кушинга / Под ред. И.И. Дедова, Г.А. Мельниченко. М., 2011. 342 с.
  3. Gennari С., Imbimbo B., Montagnani M., Bernini M., Nardi P., Avioli L.V. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif. Tissue Int. 1984;36:245-52.
  4. Adinoff A.D., Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma. N. Engl. J. Med. 1983;309:265-68.
  5. Luengo M., Picado C., Del Rio L., Guanabens N., Montserrat J.M., Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax. 1991;46(11):803-6.
  6. Lekamwasam S., Adachi J.D., Agnusdei D., Bilezikian J., Boonen S., Borgström F., Cooper C., DiezPerez A., Eastell R., Hofbauer L.C., Kanis J.A., Langdahl B.L. Lesnyak O., Lorenc R., McCloskey E., Messina O.D., Napoli N., Obermayer-Pietsch B., Ralston S.H., Sambrook P.N., Silverman S., Sosa M., Stepan J., Suppan G., Wahl D.A., Compston J.E. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23:2257-76.
  7. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 2000;15:993-1000.
  8. Recommendation for prevention and treatment of glucocorticoid-induced OSteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Arthritis & Rheumatism. 2001;44(7):1496-503.
  9. Van Staa T.P., Leufkens H.G.M., Cooper C. Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. 2001;16:581-88.
  10. Баранова И.А., Чучалин А.Г. Остеопороз в пульмонологии: особенности возникновения, течения, диагностики и лечения у больных бронхиальной астмой. В кн.: Руководство по остеопорозу / Под ред. Л.И. Беневоленской. М., 2003;397-429.
  11. Gallagher J.C. The effects of calcitriol on falls and fractures and physical perfomance tets. J. Steroid Biocheistry& Molecular Biology. 2004;89-90:497-501.
  12. Марченкова Л.А., Полякова Е.Ю., Древаль А.В. и др. Влияние системных и ингаляционных глюкокортикоидов на риск развития остеопороза у женщин, страдающих бронхиальной астмой в периоде постменопаузы. Остеопороз и остеопатии. 2004;3:8-12.
  13. Manning P.J., Evans M.C., Reid I.R. Normal bone mineral density following cure of Cushing's syndrome. Clin. Endocrinol. 1992;36:229-34.
  14. Hofbauer L.C., Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol. Endocrinol. 2009;23:1525-31.
  15. Rizzoli R., Adachi J.D., Cooper C., Dere W., Devogelaer J.P., Diez-Perez A., Kanis J.A., Laslop A., Mitlak B., Papapoulos S., Ralston S., Reiter S., Werhya G., Reginster J.Y. Management of Glucocorticoid-Induced Osteoporosis. Calcif. Tissue Int. 2012;91:225-43.
  16. Rochefort G.Y., Pallu S., Benhamou C.L. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int. 2010;21:1457-69.
  17. den Uyl D., Bultink I.E., Lems W.F. Advances in glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep. 2011;13:233-40.
  18. Gulko P.S., Mulloy A.L. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin. Exp. Rheumatol. 1996;14 (2):199-206.
  19. Lane N.E. An update on glucocorticoid-induced osteoporosis. Rheum. Dis.Clin. North Am. 2001;27(1):131-36.
  20. Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoids -induced osteoporosis. Endocrinology. 1999;140:4382-89.
  21. Eastеll R. Patogenesis of postmenopausal osteoporosis. In Textbook: Primer on the Metabolic Bone Diseases and Disorders of mineral Metabolism. Murray J. Favus, M.D. Lippincott Williams & Wilkins. 1999. 502 p.
  22. Adachi J.D., Bensen W.G., Bianchi F., Cividino A., Pillersdorf S., Sebaldt R.J., Tugwell P., Gordon M., Steele M., Webber C., Goldsmith C.H. Vitamin D and calcium in prevention of corticosteroid-induced osteoporosis: A 3-year follow-up. J. Rheumatol. 1996;23:995-1000.
  23. Schacht E., Strategic Business Unit Bone, Byk Gulden. Обоснование назначения альфакальцидола (Альфа Д3-Тева) для лечения инволютивного остеопороза у женщин, а также для профилактики и лечения кортикоидиндуцированного остеопороза. Международный эндокринологический журнал. 2010;6(30).
  24. Kanis J.A., Johansson H., Oden A., Johnell O., de Laet C., Melton III L.J., Tenenhouse A., Reeve J., Silman A.J., Pols H.A, Eisman J.A., McCloskey E.V., Mellstrom D. A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Miner. Res. 2004;19:893-99.
  25. Lado Abeal J., Rodrigues Arnao J., Newell Price J.D., et al. Menstrual abnormalities in women with Cushing's diseases are correlated with hypercortisolemia rather than raised circulating androgen levels. J. Clin. Endocrin. Metab. 1998;83(9):3083-88.
  26. Eastеll R., Reid D.M., Compston J., Cooper C., Fogelman I., Francis R.M., Hosking D.J., Purdie D.W., Ralston S.H., Reeve J., Russell R.G., Stevenson J.C., Torgerson D.J. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J. Intern. Med. 1998;244:271-92.
  27. Van Staa T.P, Laan R.F., Barton I.P., et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224-29.
  28. De Nijs R.N., Jcobs J.W., Algra A., et al. Prevention and treatment of glucorticoid-induced osteoporosis with active vitamin D3 analogues; a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos. Int. 2004;15(8):589-602.
  29. Ringe J.D., Dorst A., Faber H., Schacht E., Rahlfs V.W. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol. Int. 2004; 24:63-70.
  30. Vestergaad P, Olsen M.L, Paaske J.S, Rejnmark L, Sorensen H.T., Mosekilde L. Corticosteroid use and risk of hip fracture: a population - based case control study in Denmark. J. Intern. Med. 2003;254(5):486-93.
  31. Остеопороз: диагностика, профилактика и лечение (клинические рекомендации) / Под ред. О.М. Лесняк, Л.И. Беневоленской, 2-е изд. М., 2009. 272 с.
  32. Geusens P.P., De Nijs R.N., Lems W.F., Laan R.F., Struijs A., van Staa T.P., Bijlsma J.W. Prevention of glucocorticoid-induced osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann. Rheum. Dis. 2004;63:324-5.
  33. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 2007;356(18):1809-22.
  34. Ершова О.Б., Назарова А.В., Белова К.Ю., Ганерт О.А., Романова М.А., Синицына О.С. Фармакотерапия глюкокортикоидного остеопороза, Медицинский совет. 2014;10:90-7.
  35. Scharla S.H., Schacht E., Bawey S., Kamilli I., Holle D., Lempert U.G. Pleotropic effects of 1a-hydroxyvitamin D (alfacalcidol) in poatients with rheumatoid arthritis. Bone (submuitted).
  36. Boland R. Role of vitamin D in skeletal muscle function. Endocr. Rev. 1986;7:434-48.
  37. De Luca H.F., Cantorna M.T. Vitamin D: its role and users in immunology. FASEB J. 2001;15(14):2579-85.
  38. Ebert-Duming R., Jovanovic M., Kohrle J., Jacob F. Human 25(OH) vitamin D3-1a-hydroxylase promoter is regulated by TNFa-in HepG2 and HEK-293 cell lines. Exp. Clin. Endocrinol. Diabetes 2001;109(Suppl. 1):26.
  39. Schacht E. Rational for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoiporosis with alfacalcidol. Calcif. Tissue Int. 1992;65:317-27.
  40. Felsenberg D., Bock O., Borst H., et al. Additive Impact of Alfacalcidol on Bone Mineral Density and Bone Strength in Alendronate Treated Postmenopausal Women with Reduced Bone Mass. J. Musculoskeletal & Neuronal Interact. 2011;11(1):34-45.
  41. Orimo H., Nakamura T., Fukunaga M., Ohta H., Hosoi T., Uemura Y., Kuroda T., Miyakawa N., Ohashi Y., Shiraki M. Effects of Alendronate plus Alfacalcidol in Osteoporosis Patients with a High Risk of Fracture: The Japanese Osteoporosis Intervention Trial (JOINT) - 02. Current medical research and opinion 2011; 27(6):1273-84.
  42. Ringe J.D., Farahmand P., Schacht E., Rozehnal A. Superiority of a Combined Treatment of Alendronate and Alfacalcidol Compared to the Combination of Alendronate and Plain Vitamin D or Alfacalcidol Alone in Established Postmenopausal or Male Osteoporosis (AAC-Trial). Rheumatology international. 2007;27(5):425-34.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies